European Psychiatry - Volume 33 - March 2016

102 / 812

S98 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115
Conclusions Deficits in recognition of specific facial emotions
may reflect severity of psychiatric symptoms. They may be related
to specific clusters of psychotic symptoms, which need to be con-
firmed in further studies.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC63
Differential serum acute-phase
biomarker profile in schizophrenia
and bipolar disorder
B. Arranz ∗, M. Sanchez , M. Garriga , G. Safont ,
P. Garcia-Portilla , P. Sierra , L. San
1 Parc Sanitari Sant Joan de Deu, CIBERSAM, CSMA Cornella,
Barcelona, Spain
2 Hospital Mutua Terrassa, Department of Psychiatry, Terrassa, Spain
3 Hospital Clinic, Department of Psychiatry, Barcelona, Spain
4 University of Oviedo, CIBERSAM, Area de Psiquiatría, Oviedo, Spain
5 Universidad de Valencia, Department of Psychiatry, Valencia, Spain
∗ Corresponding author.
There is a growing interest in inflammation and immune dys-
function in severe psychiatric disorders such as schizophrenia and
bipolar disorder. This dysfunction seems to consist in abnormal
blood levels of cytokines and acute-phase proteins, with increased
levels of C-reactive protein (CRP), fibrinogen, homocysteine and
erythrocyte sedimentation rate (ESR). Higher levels can be found
in acute episodes and in patients with a higher cardiovascular risk.
Acute-phase protein serum parameters were determined in a
sample of 100 outpatients with schizophrenia (n = 50) or bipolar
disorder (n = 50) so as to assess differences in pro-inflammatory
state. Metabolic state was assessed through BMI, waist circumfer-
ence, glucose, cholesterol and triglyceride levels.
The whole sample showed higher levels of fibrinogen (mean
4 ±0.9 g/L), triglycerids (mean 2.9 ±8.5mmol/L), cholesterol-
LDL (mean 3 ± 0.9mmol/L), and homocysteine (mean
16.2 ± 7.3 umol/L) than our laboratory reference values from
healthy individuals.
After correcting for gender and pharmacological treatment,
patients with schizophrenia showed higher levels of ESR, fibrino-
gen, glucose and CRP, while homocysteine was not statistically
different between patients with schizophrenia or bipolar disorder
(see
These results may suggest a different biomarker profile in
bipolar and schizophrenic outpatients, with a more severe pro-
inflammatory state in schizophrenia. Serum homocysteine levels
could be a state marker in both disorders.
Table 1
ESR (mm) Fibrinogen
(g/L)
Glucose
(mmol/L)
CRP (mg/L) Homocysteine
(mmol/L)
Schizophrenia 6 ± 5.7 4.1 ± 0.85 5.7 ± 2.0 5.4 ± 4.2 17.1± 8.6
Bipolar disorder 3.1 ± 2.2* 3.6 ± 0.76* 4.4 ± 0.95* 2.2 ± 2.0* 15.9± 5.7 (NS)
NS: not significant. * P<0.05.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC64
Akathisia: Prevalence and risk factors
in a community-dwelling sample of
patients with schizophrenia. Results
from the multi-center FACE-SZ
Dataset
F. Berna ∗, D. Misdrahi , L. Boyer , P.M. Llorca , G. Fond ,
W.G. Face-sz
1 Hôpitaux Universitaires de Strasbourg, Inserm U1114, FMTS,
Fondation FondaMental, Psychiatry, Strasbourg cedex, France
2 Centre Hospitalier Charles-Perrens Bordeaux, CNRS UMR 5287,
INCIA, Fondation FondaMental, Psychiatry, Bordeaux, France
3 CHU Sainte-Marguerite, Pôle Psychiatrie Universitaire, Marseille,
France
4 CHU de Clermont-Ferrand, Fondation FondaMental, Psychiatry,
Clermont-Ferrand, France
5 Université Paris-Est, Inserm U955 eq15, GHU Mondor, DHU Pe-psy,
Psychiatry, Créteil, France
∗ Corresponding author.
The main objective of this study was to determine the preva-
lence of akathisia in a community-dwelling sample of patients
with schizophrenia, and to determine the effects of treatments and
the clinical variables associated with akathisia. Three hundred and
seventy-two patients with schizophrenia or schizoaffective disor-
der were systematically included in the network of FondaMental
Expert Center for Schizophrenia and assessedwith validated scales.
Akathisia was measured with the Barnes Akathisia Scale (BAS).
Ongoing psychotropic treatment was recorded. The global preva-
lence of akathisia (as defined by a score of 2 or more on the
global akathisia subscale of the BAS) in our sample was 18.5%.
Patients who received antipsychotic polytherapy were at higher
risk of akathisia and this result remained significant (adjusted
odd ratio = 2.04, P = .025) after controlling the influence of age,
gender, level of education, level of psychotic symptoms, sub-
stance use comorbidities, current administration of antidepressant,
anticholinergic drugs, benzodiazepines, and daily-administered
antipsychotic dose. Our results indicate that antipsychotic poly-
therapy should be at best avoided and suggest that monotherapy
should be recommended in cases of akathisia. Long-term adminis-
tration of benzodiazepines or anticholinergic drugs does not seem
to be advisable in cases of akathisia, given the potential side effects
of these medications.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC65
Antipsychotic-induced tardive
dyskinesia: The role of glutamatergic
system
A. Boiko ∗, S. Ivanova , A. Semke
1 Mental Health Research Institute SB RAMSci, Laboratory of
Molecular Genetics and Biochemistry, Tomsk, Russia
2 Mental Health Research Institute SB RAMSci, Department of Clinical
Psychiatry, Tomsk, Russia
∗ Corresponding author.
Tardive dyskinesia (TD) occurs in 20–25% of patients with
long-term antipsychotic therapy. Abnormalities in glutamatergic
transmission are considered one of the key components of the
pathogenesis of drug-induced side effects. Glutamate acts as exci-
totoxin under certain conditions and in excessive concentrations.
Aim is to study the concentration of glutamate and analysis of sin-
gle nucleotide polymorphisms (SNP) in genes coding the glutamate
transporter andNMDA-receptors in schizophrenic patientswith TD
and without it.